LRMR | Larimar Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.87 - 4.17
52 Week Range	3.01 - 13.68
Beta	0.69
Implied Volatility	211.85%
IV Rank	64.43%
Day's Volume	1,109,952
Average Volume	859,942
Shares Outstanding	63,806,600
Market Cap	255,864,466
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-06-19

Valuation
Profitability
Growth
Health
P/E Ratio	-3.49
Forward P/E Ratio	N/A
EPS	-1.15
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	42
Country	USA
Website	LRMR

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

LRMR's peers: ADXN, ALEC, APVO, ATXS, CABA, CDMO, CNTA, COGT, CYCCP, CYCN, FENC, FGEN, HALO, GNLX, HUMA, IMCR, IMRX, INBX, JAZZ, KALV, KNSA, KRON, KROS, KURA, KZR, LGVN, LQDA, PCVX, SNDX, MRUS, STRO, CELC, IKNA, SPRO, BOLT, CHRS, GRCL, NLTX, SRZN, FIXX, DAWN, MESO, MIRM, MNKD, NVCT, OLMA, OMGA, PBYI, PHAR, QURE, RCKT, RZLT, SLDB, SYRS, TCRT, TRDA, TSHA, UTHR, VRCA, XNCR, YMAB, BLTE, MAIA, IRON

*Chart delayed

Analyzing fundamentals for LRMR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see LRMR Fundamentals page.

Watching at LRMR technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on LRMR Technicals page.